Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Heron Therapeutics (HRTX) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Heron Therapeutics (HRTX) over the last 13 years, with Q3 2025 value amounting to 0.01%.

  • Heron Therapeutics' Return on Capital Employed rose 2000.0% to 0.01% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.01%, marking a year-over-year increase of 2000.0%. This contributed to the annual value of 0.08% for FY2024, which is 6200.0% up from last year.
  • Per Heron Therapeutics' latest filing, its Return on Capital Employed stood at 0.01% for Q3 2025, which was up 2000.0% from 0.05% recorded in Q2 2025.
  • In the past 5 years, Heron Therapeutics' Return on Capital Employed ranged from a high of 0.01% in Q3 2025 and a low of 1.46% during Q2 2022
  • In the last 5 years, Heron Therapeutics' Return on Capital Employed had a median value of 0.84% in 2021 and averaged 0.69%.
  • Its Return on Capital Employed has fluctuated over the past 5 years, first plummeted by -6100bps in 2022, then soared by 7700bps in 2024.
  • Over the past 5 years, Heron Therapeutics' Return on Capital Employed (Quarter) stood at 0.84% in 2021, then fell by -16bps to 0.98% in 2022, then increased by 22bps to 0.76% in 2023, then skyrocketed by 89bps to 0.09% in 2024, then surged by 112bps to 0.01% in 2025.
  • Its Return on Capital Employed was 0.01% in Q3 2025, compared to 0.05% in Q2 2025 and 0.02% in Q1 2025.